GH Research’s (GHRS) “Buy” Rating Reaffirmed at HC Wainwright

GH Research (NASDAQ:GHRS)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $40.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 353.00% from the stock’s previous close.

Separately, Canaccord Genuity Group decreased their price objective on GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a report on Monday, November 18th.

GH Research Stock Up 0.6 %

Shares of NASDAQ:GHRS opened at $8.83 on Monday. The business’s 50 day moving average is $8.42 and its 200 day moving average is $8.96. The stock has a market cap of $459.42 million, a P/E ratio of -11.18 and a beta of 0.84. GH Research has a 52-week low of $6.00 and a 52-week high of $14.99.

Institutional Inflows and Outflows

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. lifted its position in GH Research PLC (NASDAQ:GHRS) by 1.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,686,689 shares of the company’s stock after buying an additional 85,000 shares during the period. RA Capital Management L.P. owned approximately 12.85% of GH Research worth $44,734,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).